Checkpoint Therapeutics Inc

NASDAQ:CKPT   3:59:58 PM EDT
2.51
+0.15 (+6.36%)
Other Pre-Announcement

Checkpoint Announces Positive Interim Results From Registration-Enabling Trial Of Cosibelimab

Published: 09/17/2020 11:01 GMT
Checkpoint Therapeutics Inc (CKPT) - Checkpoint Therapeutics Announces Positive Interim Results From Registration-enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma.
Checkpoint Therapeutics - 51.4% Objective Response Rate and 13.5% Complete Response Rate in Half Planned Pivotal Cohort in Cosibelimab Trial.
Checkpoint Therapeutics - Trial Continues to Enroll Patients, and Full Top-line Results Are Expected in Mid-2021.